JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

B2290 Beta-Lapachone

Target: Topoisomerases

Summary: DNA topoisomerase I inhibitor,selective

insoluble in H2O; ≥10.85 mg/mL
A8171 Entinostat (MS-275,SNDX-275)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC1 and HDAC3 inhibitor

insoluble in H2O; ≥18.8 mg/mL
A8178 Panobinostat (LBH589)
10 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor

insoluble in H2O; insoluble in EtOH; ≥17.47 mg/mL
B3589 5-BrdU

Summary: Synthetic thymidine analog
A4084 Vorinostat (SAHA, MK0683)
9 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor

insoluble in EtOH; insoluble in H2O; ≥4.41 mg/mL
A4090 JNJ-26481585
3 Citation

Target: Histone Deacetylases (HDACs)

Summary: Potent HDAC inhibitor

insoluble in H2O; insoluble in EtOH; ≥19.2 mg/mL
A4096 Belinostat (PXD101)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: Hydroxamate-type HDAC inhibitor

insoluble in H2O; ≥15.92 mg/mL
A4104 AR-42 (OSU-HDAC42)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor,novel and potent

insoluble in EtOH; insoluble in H2O; ≥15.62 mg/mL
A1912 Lomeguatrib

Target: O6-methylguanine-DNA-methyl-transferase (MGMT)

Summary: MGMT inhibitor

≥50 mg/mL
A3872 TH-302

Summary: Hypoxia-activated prodrug,inhibits H460/HT29 cell growth

≥22.45 mg/mL